Overview


According to FutureWise analysis, the market for IPV Vaccines is expected to grow with a CAGR of 8.5% over the forecast period 2023-2031, and reach a market value of US$ 0.36 billion by 2031.

IPV vaccine, also known as inactivated poliovirus vaccine, is a vaccine that protects against polio. The IPV contains killed poliovirus strains, so it cannot cause the disease. It stimulates the body's immune system to produce antibodies against the virus, providing immunity. It is given by injection into the muscle of the arm or leg. IPV is a safe and effective vaccine. It is very good at preventing polio and does not have a small risk of causing polio associated with the oral polio vaccine (OPV). IPV is also recommended for adults who have not been vaccinated against polio or are unsure of their vaccination status. The most common side effects are mild and go away on their own within a few days. These side effects may include soreness, redness, headache, swelling at the injection area, fatigue, and low-grade fever.

There are various brands of polio vaccines. Each vaccine plays a crucial role in the global effort to eliminate polio, a highly infectious viral disease that may lead to paralysis and even death. Poliovac (Pfs/Sd) is one of the vaccines in use, designed to protect individuals against the poliovirus. Similarly, shanipv, poliorix, ipol/imovax, and polymilex are also respected brands in the fight against polio. These vaccines work by boosting the body's immune system to recognize and defend against the poliovirus, thereby providing immunity to the disease. Efforts to combat polio involve extensive vaccination campaigns, especially in regions where the virus still poses a threat. These vaccines are administered through various methods, including oral drops and injections, tailored to suit different age groups and population demographics.

FutureWise Market Research has published a report that provides an insightful analysis IPV vaccines market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts IPV vaccines market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • GlaxoSmithKline Plc
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • PT Bio Farma
  • AJ Vaccines.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The growing awareness of the crucial role vaccinations play in disease prevention has significantly bolstered the demand for IPV vaccines. As communities become increasingly informed about the benefits of immunization, there is a heightened willingness to seek and administer vaccines like IPV, leading to a sustained market demand. Furthermore, technological advances in biotechnology and vaccine development have revolutionized the production process, creating highly effective and efficient IPV vaccines. These technological advancements not only enhance the vaccine's efficacy but also streamline production, making them more accessible and appealing to both healthcare providers and the general population, thereby further propelling market growth. Also, governments worldwide have instituted vigorous immunization programs, wherein the administration of IPV to infants and children is a cornerstone. This concerted effort ensures a consistent and reliable demand for IPV vaccines. These well-structured programs prioritize the health of young populations and foster a culture of routine immunization, establishing IPV as an essential component of public health initiatives. As a result, the steady inclusion of IPV in government-endorsed vaccination schedules creates a stable and enduring market demand, providing a foundational driver for the IPV vaccine market. However, the presence of Oral Polio Vaccine (OPV), an alternative polio vaccine administered orally, presents a significant obstacle for the IPV vaccine market. As an equally effective and less expensive alternative, OPV may divert demand away from IPV. This competition might be a restraint on the market as healthcare providers and policymakers may face the decision of choosing between the two vaccines based on factors like cost, ease of administration, and local prevalence of polio strains. Additionally, convincing stakeholders to switch to IPV may require substantial efforts and resources in regions where OPV is traditionally favored or integrated into vaccination programs. Therefore, the ongoing presence and preference for OPV in some areas may hinder the market growth of IPV vaccines.

By Vaccine Brand

  • Poliovac (Pfs/Sd)
  • Shanipv
  • Poliorix
  • Ipol/Imovax
  • Polymilex

By Distribution Channel

  • Private
  • Public

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to the rising government support to increase immunization, increasing initiatives by key players to develop and launch inactivated polio vaccines, increased awareness regarding vaccination, and high demand for inactivated polio vaccines (IPV) are the factors that is expected to boost the growth of target market over the forecast period. Furthermore, technological advancements, well-developed healthcare infrastructure, and growing research and development are further driving the market expansion. Therefore, the above-mentioned factors are anticipated to provide new promising opportunities leading to the growth of the IPV Market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the IPV Vaccines Market By Vaccine Brand, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  IPV Vaccines Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of IPV Vaccines Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  IPV Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  IPV Vaccines Market, By Vaccine Brand Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Poliovac (Pfs/Sd)
      2. Shanipv
      3. Poliorix
      4. Ipol/Imovax
      5. Polymilex
  • 8.  IPV Vaccines Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
      1. Private
      2. Public
  • 9.  North America IPV Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.  Latin America IPV Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.  Europe IPV Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.  Asia Pacific IPV Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.  Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline Plc
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2.  Sanofi S.A.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3.  Serum Institute of India Pvt. Ltd.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4.  PT Bio Farma
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. AJ Vaccines
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients